The former is explained by the different potency of ERK activation between these two LUAD oncoproteins and is in line with the fact that KRAS mutations are not detected in SCLC specimens (Peifer et al., 2012; George et al., 2015). This evidence concerns the gene KRAS and small cell lung carcinoma.